What is it about?
Immunogenicity of hepatitis B vaccine between 20 μg with 3-dose schedule and 60 μg with 2-dose regimens was compared 2 years after primary immunization. The seroprotection rates in group A (20 μg,0-1-6 month), B (60μg,0-1month) and C (60μg,0-2 month) were 98.31%, 88.37% and 85.19%, respectively (P = 0.014), and the GMC level of anti-HBs antibody in group A was significantly higher than those of other two groups (427.46 mIU/ml vs. 89.74 mIU/ml,89.80 mIU/ml, respectively; all P < 0.01).
Featured Image
Why is it important?
Our finding suggested that the standard 20 mg (0–1–6 month) regimen of hepatitis B vaccine should be recommended as a priority on the premise of complete compliance in adults
Perspectives
Doing vaccine-related studies is my great pleasure.
Dr Xueen Liu
Peking University Health Science Center
Read the Original
This page is a summary of: Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study, Human Vaccines & Immunotherapeutics, February 2018, Taylor & Francis,
DOI: 10.1080/21645515.2018.1438090.
You can read the full text:
Contributors
The following have contributed to this page
